Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals Tushar SrivastavaNicholas R. LatimerPaul Tappenden Practical Application 19 May 2021 Pages: 869 - 878
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies Ana DuarteSimon WalkerMark Sculpher Review Article 19 June 2021 Pages: 879 - 887
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector Irina PokhilenkoLuca M. M. JanssenAggie T. G. Paulus Systematic Review Open access 14 June 2021 Pages: 889 - 900
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries Kate WilliamsDaniel AggioYan Wang Original Research Article Open access 01 July 2021 Pages: 901 - 912
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study Becky PenningtonAbualbishr AlshreefJohn Brazier Original Research Article Open access 26 April 2021 Pages: 913 - 927
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population Emily McDoolClara MukuriaJohn Brazier Original Research Article Open access 27 May 2021 Pages: 929 - 940
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden Fredrik O. L. NilssonSandra T. AsaninSarah Smith Original Research Article Open access 03 June 2021 Pages: 941 - 952
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer Yat Hang ToKoen DegelingJeanne Tie Original Research Article 05 June 2021 Pages: 953 - 964
Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening” James F. O’Mahony Letter to the Editor 17 July 2021 Pages: 965 - 967
Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening Edna KeeneyHoward ThomSabina Sanghera Letter to the Editor 17 July 2021 Pages: 969 - 970
Retraction Note to: The EQ-5D-5L Valuation Study in Egypt Sahar A. Al ShabasyMaggie M. AbbassiSamar F. Farid Retraction Note Open access 15 June 2021 Pages: 971 - 971